Modern oncohematology is developing rapidly, and the advent of targeted therapy has truly changed approaches to treating chronic lymphocytic leukemia. A decade ago, exhausting chemotherapy remained the standard option, which the elderly body endured with great difficulty. Today, second-generation Bruton’s tyrosine kinase inhibitors dominate medical practice. They block a specific protein involved in the development of abnormal B cells, allowing the disease to be kept under reliable control.
When it comes to choosing a specific prescription, hematologists most often compare options such as Brukinsa and Calquence. Both have high efficacy, but differ in pharmacological profile, interaction with other drugs, and impact on the cardiovascular system. For older people, these exact nuances become decisive when choosing therapy.
Table of Contents
What Clinical Trials Show About Efficacy
Each medication Brukinsa vs Calquence – is effective in controlling the disease. Still, a direct and indirect comparison of clinical trials reveals a few subtle differences in the progress-free survival time. Data from the ALPINE and ASCEND studies, when analyzed, suggest that Brukinsa has some advantages in terms of the duration of remission maintenance and a higher percentage of complete responses in patients.
Dr. Daniel Ermann’s team at the Huntsman Cancer Institute presented some findings with the data at ASCO 2026 about over 10,000 Medicare patients who had used these prescriptions as their very first treatment. The results showed that people on Brukinsa stayed on their initial therapy longer and had a slightly better two-year survival rate about 86% compared to 80% for Calquence. For someone in their late 70s or 80s, this offers a practical benefit: keeping the condition stable on the first attempt, without the stress of switching drugs or altering the treatment routine.
Mechanism of Action and Selectivity of Impact
Both options were developed as more targeted successors to first-generation drugs. They act selectively by binding to the tyrosine kinase enzyme and suppressing signals that force tumor cells to proliferate. Thanks to this, normal healthy tissues undergo minimal destructive impact, which is critically important at age 70 or 80.
The difference lies in the molecular structure. Calquence was developed with high selectivity for a specific enzyme, reducing overall toxicity. Brukinsa, in turn, has the property of providing long-term and complete binding of the target protein throughout the day due to high plasma concentration. This yields a stable result without dips in efficacy between doses.
Cardiovascular Safety Profile
For older patients, heart condition is often a concurrent limitation. First-generation drugs frequently caused atrial fibrillation, hypertensive crises, or bleeding. Both newer options demonstrate a much higher level of safety regarding heart rhythm.
The incidence of heart rhythm disorders with these substances remains low, accounting for only a few percent. Calquence and Brukinsa show similar, very favorable results regarding the frequency of cardiac complications compared to previous standards of care.
Before prescribing a regimen, the doctor necessarily evaluates the following important factors:
- Presence of arrhythmia, heart failure, or hypertension in the patient’s history.
- Use of blood thinners or presence of a predisposition to bleeding.
- Need for continuous use of medications for high stomach acidity.
- Individual genetic characteristics of the tumor, including the presence of specific mutations.
- Overall functional state of the kidneys and liver.
All these factors are weighed in combination. After all, the goal is not simply tumor suppression, but also preserving stable operation of all body systems.
Taking the Medicine: How Easy Is the Routine?
Daily dosing also works a bit differently for each drug. Calquence is strictly taken twice a day, about 12 hours apart. Brukinsa offers more flexibility: you can either take it twice daily or as a single dose once a day. For someone already managing multiple morning pills, a once-daily option is often much easier to stick to.
Mixing With Other Prescriptions
In old age, people often take a whole list of medications for concomitant conditions. Here, the question of chemical compatibility arises. For example, Calquence requires a certain level of stomach acidity for full absorption. If a patient simultaneously takes medications for heartburn or ulcers, this can reduce drug absorption.
Brukinsa is less sensitive to pH levels in the gastrointestinal tract. It absorbs well regardless of whether a person takes stomach acid reducers. In addition, Calquence can sometimes cause mild headaches in the first weeks of administration, which usually resolve on their own, whereas Brukinsa is more characterized by temporary changes in blood tests that require standard laboratory monitoring.
Staying on Therapy: What to Expect Long-Term
Targeted treatment is usually designed for a long period. It is a continuous process that allows a person to live a normal life: attend to household chores, take walks, and communicate with loved ones. Both options are well tolerated by the body, rarely forcing the course to be interrupted due to severe side effects.
Long-term follow-up analyses show that the majority of people in the older age group maintain a high level of daily activity. They do not experience constant exhausting nausea or weakness characteristic of past treatment methods.
How Doctors Pick the Right Option for You
No single therapy works exactly the same for everyone. The final decision is always made by an experienced hematologist together with the patient. The doctor thoroughly reviews the patient’s laboratory tests, cytogenetic markers, presence of cardiac or renal co-morbidities, and the prior therapy history. The smallest things can affect the choice of therapy; the patient can be taking other pills or have some habit which may not look important to many, but in fact, can affect the therapy choice.
Also, doctors consider how potential side effects may affect quality of life. For instance, if a patient has a history of severe acid reflux (and needs daily acid reducers that block Calquence absorption) or requires antiplatelet therapy (blood thinners that raise bleeding risks for both drugs), these medical details largely determine the choice of a treatment that will best suit the individual for safety and effectiveness.
Thus, thanks to the emergence of Brukinsa and Calquence, chronic lymphocytic leukemia in old age has moved into the category of manageable conditions. The main thing is to undergo timely examinations, adhere to the dosing schedule, report any new symptoms early, and stay in close contact with your care team. Continuous monitoring ensures that therapy remains both safe and sustainable over time.
